Parkinson's disease and migraine
https://doi.org/10.14412/2074-2711-2025-3-98-103
Abstract
Parkinson's disease (PD) is one of the most common neurodegenerative disorders. Migraine is the most prevalent neurological condition among adults. It has been established that migraine often precedes the development of PD, and with the onset of motor symptoms and/or the initiation of specific therapy, both the frequency and severity of migraine attacks significantly decrease. It is likely that the two conditions share common functional and biochemical characteristics. If brainstem nuclei disintegration and dopaminergic neurotransmission dysregulation are involved in the pathogenesis of migraine, then studying patients with migraine who go on to develop PD may provide important insights into the role of dopamine and/or dopaminergic brainstem regions in the pathogenesis of both migraine and PD. This review focuses on studies addressing epidemiology, the role of dopaminergic system genes in migraine development, mechanisms linking the two diseases, and the impact of pharmacological therapy.
Keywords
Supporting agencies: The article is sponsored by Servier.
About the Authors
Z. A. Zalyalova
Kazan State Medical University, Ministry of Health of Russia; Consultative and Diagnostic Center for Extrapyramidal Disorders and Botulinum Therapy
Russian Federation
Competing Interests:
Russian Federation
Zuleikha Abdullazyanovna Zalyalova
49, Butlerova St., Kazan 420012
5, Isaeva St., Kazan 420061
Competing Interests:
The conflict of interests did not affect the results of the study
E. A. Katunina
Department of Neurology, Neurosurgery and Medical Genetics,
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Department of Neurodegenerative Diseases, Federal Center for Brain and Neurotechnologies, FMBA of Russia
Russian Federation
Competing Interests:
Russian Federation
1, Ostrovityanova St., Moscow 117997
1, Ostrovityanova St., Build. 10, Moscow 117997
Competing Interests:
The conflict of interests did not affect the results of the study
D. V. Pokhabov
Department of Nervous Diseases, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia; Center for Innovative Neurology, Extrapyramidal Diseases and Botulinum Therapy, Federal Siberian Research Clinical Center
Russian Federation
Competing Interests:
Russian Federation
1, Partizana Zheleznyayka St., Krasnoyarsk 660022
26, Kolomenskaya St., Krasnoyarsk 660037
Competing Interests:
The conflict of interests did not affect the results of the study
References
1. Azimova YuE, Amelin AV, Alferova VV, et al. Clinical guidelines “Migraine". Zhurnal nevrologiii psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1-3):4-36. doi: 10.17116/jnevro20221220134 (In Russ.)].
2. Ali MD, Gayasuddin Qur F, Alam MS, et al. Global Epidemiology, Clinical Features, Diagnosis and Current Therapeutic Novelties in Migraine Therapy and their Prevention: A Narrative Review. Curr Pharm Des. 2023;29(41):3295-311. doi: 10.2174/0113816128266227231205114320
3. Shtok VN, Ivanova-Smolenskaya IA, Levin OS, editors. Extrapyramidal disorders. Guide to diagnostics and treatment. Moscow: MEDpress-inform; 2002. 608 p. (In Russ.)].
4. Parkinson’s disease, secondary parkinsonism and other diseases that manifest as parkinsonism syndrome. Clinical Recommendations. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/716_1 (In Russ.)].
5. Tysnes O-B, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017 Aug;124(8):901-5. doi: 10.1007/s00702-017-1686-y. Epub 2017 Feb 1.
6. Ashina S, Bentivegna E, Martelletti P, Eikermann-Haerter K. Structural and Functional Brain Changes in Migraine. Pain Ther. 2021 Jun;10(1):211-23. doi: 10.1007/s40122-021-00240-5. Epub 2021 Feb 16.
7. Barbanti P, Fofi L, Aurilia C, Egeo G. Dopaminergic symptoms in migraine. Neurol Sci. 2013 May;34 Suppl 1:S67-70. doi: 10.1007/s10072-013-1415-8
8. Ha WS, Kim J, Hwang HW, et al. The association between migraine and Parkinson's disease: a nationwide cohort study. Epidemiol Health. 2024;46:e2024010. doi: 10.4178/epih.e2024010. Epub 2023 Dec 18.
9. Todt U, Netzer C, Toliat M, et al. New genetic evidence for involvement of the dopamine system in migraine with aura. Hum Genet. 2009 Apr;125(3):265-79. doi: 10.1007/s00439-009-0623-z. Epub 2009 Jan 17.
10. Fernandez F, Lea RA, Colson NJ, et al.Association between a 19 bp deletion polymorphism at the dopamine beta-hydroxylase (DBH) locus and migraine with aura. J Neurol Sci. 2006 Dec 21;251(1-2):118-23. doi: 10.1016/j.jns.2006.09.013. Epub 2006 Nov 7.
11. Sergeev AV, Guziy EA, Kovalchuk NA, et al. The role of dopaminergic system genes in the development of chronic migraine and drug-induced headache. Rossiyskiy zhurnal boli = Russian Journal of Pain. 2024;22(4):24-9. doi: 10.17116/pain20242204124 (In Russ.)].
12. Nunes JC, Costa Bergamaschi EN, Freitas FC, et al. Prevalence of headache in patients with Parkinson's disease and its association with the side of motor symptom onset. Neurol Sci. 2014 Apr;35(4):595-600. doi: 10.1007/s10072-013-1571-x. Epub 2013 Nov 7.
13. Suzuki K, Okuma Y, Uchiyama T, et al. The prevalence, course and clinical correlates of migraine in Parkinson's disease: A multicentre case-controlled study. Cephalalgia. 2018;38:1535-44. doi: 10.1177/0333102417739302
14. Sampaio Rocha-Filho PA, Leite Souza-Lima CF. Parkinson's disease and headaches: A cross-sectional study. Headache. 2020;60:967-73. doi: 10.1111/head.13815
15. Angelopoulou E, Papadopoulos AN,Spantideas N, Bougea A. Migraine, tensiontype headache and Parkinson's Disease: A systematic review and meta-analysis. Medicina. 2022;58:1684. doi: 10.3390/medicina58111684
16. Zalyalova ZA, Yakovleva LA, Altunbaev RA. Pain syndrome in Parkinson's disease. Zhurnal nevrologiii psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(3):79-81 (In Russ.)].
17. Scher AI, Ross GW, Sigurdsson S, et al. Midlife migraine and late-life parkinsonism: AGES-Reykjavik study. Neurology. 2014 Sep 30;83(14):1246-52. doi: 10.1212/WNL.0000000000000840. Epub 2014 Sep 17.
18. Wang HI, Ho YC, Huang YP, Pan SL. Migraine is related to an increased risk of Parkinson's disease: A population-based, propensity score-matched, longitudinal followup study. Cephalalgia. 2016 Dec;36(14):131623. doi: 10.1177/0333102416630577. Epub 2016 Feb 6.
19. De Oliveira Vilaca C, Leite MA, de Souza JA, et al. The Behavior of Migraine in Patients with Parkinson's Disease. Neurol Int. 2015 Dec 21;7(3):6133. doi: 10.4081/ni.2015.6133
20. Barbanti P, Fabbrini G, Vanacore N, et al.Dopamine and migraine: does Parkinson's disease modify migraine course? Cephalalgia. 2000 Oct;20(8):720-3. doi: 10.1111/j.1468-2982.2000.00123.x
21. Jatale V, Tiwari A, Kumar M, et al.Migraine and Tension-type Headache in Parkinson's Disease and Progressive Supranuclear Palsy/Corticobasal Syndrome. Ann Indian Acad Neurol. 2023 SepOct;26(5):708-14. doi: 10.4103/aian.aian_604_23. Epub 2023 Sep 25.
22. Jurado-Coronel JC, Cabezas R, Avila Rodriguez MF, et al. Sex differences in Parkinson's disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics. Front Neuroendocrinol. 2018 Jul;50:18-30. doi: 10.1016/j.yfrne.2017.09.002. Epub 2017 Sep 30.
23. Liampas I, Mylonas KS, Brotis A, et al. Serum lipid abnormalities in migraine: A meta-analysis of observational studies. Headache. 2021 Jan;61(1):44-59. doi: 10.1111/head.14039. Epub 2021 Jan 4.
24. Peroutka SJ, Wilhoit T, Jones K. Clinicalsusceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology. 1997 Jul;49(1):201-6. doi: 10.1212/wnl.49.1.201
25. Emin Erdal M, Herken H, Yilmaz M,Bayazit YA. Significance of the catechol-Omethyltransferase gene polymorphism in migraine. Brain Res Mol Brain Res. 2001 Oct 19;94(1-2):193-6. doi: 10.1016/s0169328x(01)00219-4
26. Cevoli S, Mochi M, Scapoli C, et al. A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur J Neurol. 2006 Sep;13(9):1009-13. doi: 10.1111/j.1468-1331.2006.01415.x
27. Indo T, Naito A, Sobue I. Clinical characteristics of headache in Parkinson's disease. Headache. 1983 Sep;23(5):211-2. doi: 10.1111/j.1526-4610.1983.hed2305211.x
28. Meco G, Frascarelli M, Pratesi L, et al. Headache in Parkinson's disease. Headache. 1988 Feb;28(1):26-9. doi: 10.1111/j.13652524.1988.hed2801026.x
29. Van Hilten JJ. The migraine-dopamine link: do migraine and Parkinson's disease coexist? Clin Neurol Neurosurg. 1992;94 Suppl:S168-70. doi: 10.1016/0303-8467(92)90060-g
30. Cubo E, Kompoliti K, Leurgans SE,Raman R. Dopaminergic hypersensitivity in patients with Parkinson disease and migraine. Clin Neuropharmacol. 2004 Jan-Feb;27(1):30-2. doi: 10.1097/00002826-200401000-00009
31. Парфенов ВА, Пожидаев КА. Хроническая мигрень в пожилом возрасте. Клиническая геронтология. 2019;25(5-6):47-51. doi: 10.26347/1607-2499201905-06047-0151 [Parfenov VA, Pozhidaev K.A. Chronic migraine in the elderly. Klinicheskaya gerontologiya = Clinical Gerontology. 2019;25(5-6):4751. doi: 10.26347/1607-2499201905-060470151 (In Russ.)].
32. Charbit AR, Akerman S, Goadsby PJ.Dopamine: what's new in migraine? Curr Opin Neurol. 2010;23:275-81. doi: 10.1097/WCO.0b013e3283378d5c
33. Akerman S, Goadsby PJ. Dopamine and migraine: biology and clinical implications. Cephalalgia. 2007 Nov;27(11):1308-14. doi: 10.1111/j.1468-2982.2007.01478.x
34. Page MJ, McKenzie JE, Bossuyt PM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71
35. Lin YK, Tsai CL, Lin GY, et al.Pathophysiology of Chronic Migraine: Insights from Recent Neuroimaging Research. Curr Pain Headache Rep. 2022 Nov;26(11):843-54. doi: 10.1007/s11916-022-01087-x. Epub 2022 Oct 7.
36. Niddam DM, Lai KL, Tsai SY, et al.Neurochemical changes in the medial wall of the brain in chronic migraine. Brain. 2018 Feb 1;141(2):377-90. doi: 10.1093/brain/awx331
37. Albrecht DS, Mainero C, Ichijo E, et al.Imaging of neuroinflammation in migraine with aura: a [11C]PBR28 PET/MRI study. Neurology. 2019;92:e2038-e2050. doi: 10.1212/WNL.0000000000007371
38. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994 Dec;50(4):1088-101.
39. Katunina EA, Zalyalova ZA, Pokhabov DV, et al. Parkinson's disease. Focus on early stages. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(3):95-103. doi: 10.14412/2074-27112023-3-95-103 (In Russ.)].
40. Antonini A, Tinazzi M, Abbruzzese G, et al.Pain in Parkinson's disease: facts and uncertainties. Eur J Neurol. 2018 Jul;25(7):917-e69. doi: 10.1111/ene.13624. Epub 2018 Apr 18.
41. Fox SH, Chuang R, Brotchie JM.Serotonin and Parkinson's disease: On movement, mood, and madness. Mov Disord. 2009 Jul 15;24(9):1255-66. doi: 10.1002/mds.22473
42. Braak H, Ghebremedhin E, Rüb U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004 Oct;318(1):121-34. doi: 10.1007/s00441-0040956-9. Epub 2004 Aug 24.
43. Mendlin A, Martin FJ, Jacobs BL.Dopaminergic input is required for increases in serotonin output produced by behavioral activation: an in vivo microdialysis study in rat forebrain. Neuroscience. 1999;93(3):897-905. doi: 10.1016/s0306-4522(99)00213-4
44. Ashina S, Bendtsen L, Ashina M.Pathophysiology of tension-type headache. Curr Pain Headache Rep. 2005 Dec;9(6):415-22. doi: 10.1007/s11916-005-0021-8
45. Aggarwal M, Puri V, Puri S. Serotonin and CGRP in migraine. Ann Neurosci. 2012 Apr;19(2):88-94. doi: 10.5214/ans.0972.7531.12190210
46. Saengjaroentham C, Supornsilpchai W, Ji-Au W, et al. Serotonin depletion can enhance the cerebrovascular responses induced by cortical spreading depression via the nitric oxide pathway. Int J Neurosci. 2015 Feb;125(2):130-9. doi: 10.3109/00207454.2014.908876. Epub 2014 May 19.
47. Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis. 2012 Apr;46(1):1-18. doi: 10.1016/j.nbd.2011.12.054. Epub 2012 Jan 12.
48. Kruit MC, Launer LJ, Overbosch J, et al.Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study. Cephalalgia. 2009 Mar;29(3):351-9. doi: 10.1111/j.14682982.2008.01723.x. Epub 2008 Nov 19.
49. Chen Z, Zhao H, Chen X, et al. The increased iron deposition of the gray matter over the whole brain in chronic migraine: An exploratory quantitative susceptibility mapping study. Mol Pain. 2022 JanDec;18:17448069221074987. doi: 10.1177/17448069221074987
50. Edvinsson L. Role of CGRP in migraine.Handb Exp Pharmacol. 2019;255:121-30. doi: 10.1007/164_2018_201
51. Raffaelli B, Storch E, Overeem LH, et al.Sex Hormones and Calcitonin Gene-Related Peptide in Women With Migraine: A Cross-sectional, Matched Cohort Study. Neurology. 2023 Apr 25;100(17):e1825-e1835. doi: 10.1212/WNL.0000000000207114. Epub 2023 Feb 22.
52. Labastida-Ramirez A, Rubio-Beltran E,Villalon CM, MaassenVanDenBrink A. Gender aspects of CGRP in migraine. Cephalalgia. 2019 Mar;39(3):435-44. doi: 10.1177/0333102417739584. Epub 2017 Oct 30.
53. Thornton E, Vink R. Substance P and itstachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease. Neural Regen Res. 2015 Sep;10(9):1403-5. doi: 10.4103/16735374.165505
54. Gimeno-Ferrer F, Eitner A, Bauer R, et al.From spreading depolarization to epilepsy with neuroinflammation: The role of CGRP in cortex. Exp Neurol. 2022 Oct;356:114152. doi: 10.1016/j.expneurol.2022.114152. Epub 2022 Jun 26.
55. Di Angelantonio S, Giniatullin R, Costa V,et al. Modulation of neuronal nicotinic receptor function by the neuropeptides CGRP and substance P on autonomic nerve cells. Br J Pharmacol. 2003 Jul;139(6):1061-73. doi: 10.1038/sj.bjp.0705337
56. Svenningsson P, Palhagen S, Mathe AA. Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson's Disease with Comorbid Depression versus Patients with Major Depressive Disorder. Front Psychiatry. 2017 Jun 12;8:102. doi: 10.3389/fpsyt.2017.00102
57. Hamed SA. The vascular risk associationswith migraine: relation to migraine susceptibility and progression. Atherosclerosis. 2009 Jul;205(1):15-22. doi: 10.1016/j.atherosclerosis.2008.10.016. Epub 2008 Nov 1.
58. Krasnikov AV, Shvedkov VV, Shabalina AA, Kostyreva MV. Diagnostics of dyslipidemia in episodic migraine. Zhurnal nevrologiii psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(5):17-8. doi: 10.17116/pain2021190325 (In Russ.)].
59. Hu G, Antikainen R, Jousilahti P, et al.Total cholesterol and the risk of Parkinson disease. Neurology. 2008 May 20;70(21):1972-9. doi: 10.1212/01.wnl.0000312511.62699.a8. Epub 2008 Apr 9.
60. Nam GE, Kim SM, Han K, et al.Metabolic syndrome and risk of Parkinson disease: a nationwide cohort study. PLoS Med. 2018;15:e1002640. doi: 10.1371/journal.pmed.1002640
61. Chen H, Zhang SM, Hernaan MA, et al. Dietary intakes of fat and risk of Parkinson's disease. Am J Epidemiol. 2003;157:1007-14. doi: 10.1093/aje/kwg073
Review
For citations:
Zalyalova ZA, Katunina EA, Pokhabov DV. Parkinson's disease and migraine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2025;17(3):98-103. (In Russ.) https://doi.org/10.14412/2074-2711-2025-3-98-103
Views:
26
Email this article 